South Africa: Leading the Pharma Model
An emerging country with a dynamic market, South Africa is widely seen as the gateway to Africa. From major multinational pharmaceutical corporations to burgeoning local generic companies, a wide…
Address: Glenhove Square Building 3 71-4 th Street Houghton Estate 2198 South Africa
Tel: -479
Web: http://www.keyoncologics.co.za/
Key Oncologics (Pty) Ltd is a South African biopharmaceutical company that primarily focuses on the treatment of cancer and allied diseases. We represent international companies that do not have offices in South Africa. Our aim is to have a comprehensive range of generic and proprietary oncology products in our portfolio.
Key Oncologics (Pty) Ltd has experience in registering, marketing, selling and distributing cancer products in the South African market.
Key Oncologics (Pty) Ltd has a clinical trial division with the necessary infrastructure to conduct Oncology Clinical Trials according to GCP.
Key Oncologics is recognised for its comprehensive oncology portfolio, including both proprietary and generic products.
An emerging country with a dynamic market, South Africa is widely seen as the gateway to Africa. From major multinational pharmaceutical corporations to burgeoning local generic companies, a wide…
We interviewed Graham Somerville in 2004, the year when IHD, formerly jointly owned by 11 major pharmaceutical companies, was acquired by UTi. We are interviewing you today at the head…
Dr Pillay, South Africa recently became a member of BRICS. With this distinction, we need to improve our healthcare outcomes relative to other BRICS countries. All countries have challenges with…
The South African affiliate was established in June 2003. Could you come back on the main milestones in the company’s development from 2003 onwards? Yamanouchi as an entity was an…
Since we that came to South Africa in 2005 and interviewed you, what have been the main changes both in the market place, and within Sanofi as an organization? The…
In 2005, when Focus Reports interviewed you, you were more towards the start up phase of Pharma Dynamics; and you have significantly grown in the market since then. What new…
Mr. Ehsan, you are the General Manager of IMS Africa since January 2010. What is the strategic importance of South Africa for IMS Global and for your personal country portfolio?…
Mrs. Reid, how would you define and describe the generic part of the South African pharmaceutical market? Linda Reid: South Africa is very much a branded generics market, and not…
In 2010, South Africa officially joined the BRICS grouping. The Indian and Russian work environments are familiar to you, considering your significant experience in these countries. How would you compare…
Ms Beaumont, can you describe the association to our readers and its main objectives? Innovative Medicines South Africa (IMSA) represents manufacturers of research-based medicines, ie they market the products of…
See our Cookie Privacy Policy Here
